AU2005320349C1 - Antibodies against clostridium difficile toxins and uses thereof - Google Patents

Antibodies against clostridium difficile toxins and uses thereof Download PDF

Info

Publication number
AU2005320349C1
AU2005320349C1 AU2005320349A AU2005320349A AU2005320349C1 AU 2005320349 C1 AU2005320349 C1 AU 2005320349C1 AU 2005320349 A AU2005320349 A AU 2005320349A AU 2005320349 A AU2005320349 A AU 2005320349A AU 2005320349 C1 AU2005320349 C1 AU 2005320349C1
Authority
AU
Australia
Prior art keywords
antibody
seq
antigen binding
toxin
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2005320349A
Other languages
English (en)
Other versions
AU2005320349A1 (en
AU2005320349B2 (en
AU2005320349A8 (en
AU2005320349B8 (en
Inventor
Donna Ambrosino
Gregory J. Babcock
Theresa Broering
Robert Graziano
Hector Javier Hernandez
Israel Lowy
Robert Mandell
Deborah Molrine
William D. Thomas Jr.
Hui-Fen Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
University of Massachusetts Amherst
Original Assignee
ER Squibb and Sons LLC
University of Massachusetts Amherst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36928722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2005320349(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ER Squibb and Sons LLC, University of Massachusetts Amherst filed Critical ER Squibb and Sons LLC
Publication of AU2005320349A1 publication Critical patent/AU2005320349A1/en
Publication of AU2005320349A8 publication Critical patent/AU2005320349A8/en
Publication of AU2005320349B2 publication Critical patent/AU2005320349B2/en
Application granted granted Critical
Publication of AU2005320349B8 publication Critical patent/AU2005320349B8/en
Assigned to MEDAREX, L.L.C., UNIVERSITY OF MASSACHUSETTS reassignment MEDAREX, L.L.C. Request to Amend Deed and Register Assignors: MEDAREX, INC., UNIVERSITY OF MASSACHUSETTS
Assigned to E. R. SQUIBB & SONS, L.L.C., UNIVERSITY OF MASSACHUSETTS reassignment E. R. SQUIBB & SONS, L.L.C. Request to Amend Deed and Register Assignors: MEDAREX, L.L.C., UNIVERSITY OF MASSACHUSETTS
Publication of AU2005320349C1 publication Critical patent/AU2005320349C1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
AU2005320349A 2004-02-06 2005-02-04 Antibodies against clostridium difficile toxins and uses thereof Active 2030-02-04 AU2005320349C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54235704P 2004-02-06 2004-02-06
US60/542,357 2004-02-06
US61385404P 2004-09-28 2004-09-28
US60/613,854 2004-09-28
PCT/US2005/003725 WO2006121422A2 (en) 2004-02-06 2005-02-04 Antibodies against clostridium difficile toxins and uses thereof

Publications (5)

Publication Number Publication Date
AU2005320349A1 AU2005320349A1 (en) 2006-08-24
AU2005320349A8 AU2005320349A8 (en) 2008-08-07
AU2005320349B2 AU2005320349B2 (en) 2010-04-08
AU2005320349B8 AU2005320349B8 (en) 2010-04-22
AU2005320349C1 true AU2005320349C1 (en) 2019-06-13

Family

ID=36928722

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005320349A Active 2030-02-04 AU2005320349C1 (en) 2004-02-06 2005-02-04 Antibodies against clostridium difficile toxins and uses thereof

Country Status (28)

Country Link
US (8) US7625559B2 (enExample)
EP (3) EP1766093B1 (enExample)
JP (3) JP4588763B2 (enExample)
KR (3) KR101332994B1 (enExample)
CN (1) CN101014620B (enExample)
AT (1) ATE512986T1 (enExample)
AU (1) AU2005320349C1 (enExample)
BE (1) BE2017C023I2 (enExample)
BR (1) BRPI0507433C1 (enExample)
CA (1) CA2553946C (enExample)
CY (3) CY1111860T1 (enExample)
DK (3) DK2857418T3 (enExample)
ES (3) ES2643760T3 (enExample)
FR (1) FR17C1025I2 (enExample)
HR (1) HRP20110599T1 (enExample)
HU (3) HUE034552T2 (enExample)
LT (2) LT2857418T (enExample)
LU (1) LUC00025I2 (enExample)
MX (1) MXPA06008839A (enExample)
NL (1) NL300881I2 (enExample)
NO (2) NO340300B1 (enExample)
NZ (2) NZ548821A (enExample)
PL (3) PL1766093T3 (enExample)
PT (3) PT2270045E (enExample)
RS (1) RS51908B (enExample)
SI (3) SI2857418T1 (enExample)
WO (1) WO2006121422A2 (enExample)
ZA (1) ZA200606516B (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
NZ548821A (en) * 2004-02-06 2009-12-24 Univ Massachusetts Antibodies against clostridium difficile toxins and uses thereof
JP4744443B2 (ja) * 2004-06-28 2011-08-10 独立行政法人科学技術振興機構 毒素中和性ペプチドのスクリーニング方法とｓｔｘ２阻害性ペプチド並びにベロ毒素中和剤
US20090087478A1 (en) * 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
ES2507553T3 (es) 2006-08-02 2014-10-15 Johannes Gutenberg-Universität Mainz Fármaco contra intoxicaciones por LCT
AU2014201846B2 (en) * 2007-01-30 2016-07-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
CA3161849A1 (en) 2007-01-30 2008-08-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
US20080188007A1 (en) * 2007-02-06 2008-08-07 Meridian Life Science, Inc. Fluorescent single chain antibody and its use in detection of analytes
CN101363867B (zh) * 2008-05-26 2012-12-19 北京庄笛浩禾生物医学科技有限公司 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法
JP2011524741A (ja) * 2008-05-27 2011-09-08 協和発酵キリン株式会社 インターロイキン１０受容体（ｉｌ−１０ｒ）抗体及び使用方法
DE102008029688B4 (de) * 2008-06-24 2016-06-23 Biodics Gmbh Verfahren zum Nachweis und zur Identifikation eines varianten C. difficile Stammes in einer Probe
US8709428B2 (en) 2009-02-20 2014-04-29 Health Protection Agency Antibodies to Clostridium difficile toxins
EP2459588B1 (de) * 2009-07-27 2016-06-29 BioDics GmbH Verfahren zum nachweis und zur identifikation eines varianten c. difficile stammes in einer probe
US8889363B2 (en) 2009-07-27 2014-11-18 Biodics Method for the detection and identification of a variant C. difficile strain in a sample
US20120282274A1 (en) * 2009-11-20 2012-11-08 Northshore University Health System Research Institute Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
MX339253B (es) * 2010-04-15 2016-05-18 Progenics Pharm Inc Anticuerpos para el tratamiento de infeccion y enfermedad asociadas con clostridium dificile.
RU2630663C9 (ru) * 2010-04-15 2017-11-29 Проджиникс Фармасьютикалс, Инк. Антитела для лечения ассоциированных с clostridium difficile инфекции и заболеваний
CN103957931B (zh) 2010-09-03 2017-10-24 瓦尔内瓦奥地利有限责任公司 艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
US9771416B2 (en) * 2010-10-25 2017-09-26 National Research Council Of Canada Clostridium difficile-specific antibodies and uses thereof
US20140127215A1 (en) * 2010-12-29 2014-05-08 Cangene Corporation Clostridium difficile antigens
WO2012118693A1 (en) 2011-02-28 2012-09-07 Northshore University Healthsystem Methods of diagnosing clostridium difficile infection
CN103619871B (zh) 2011-04-22 2016-12-14 惠氏有限责任公司 涉及突变体难辨梭菌毒素的组合物及其方法
CA2846486C (en) * 2011-07-12 2019-08-20 Philadelphia Health & Education Corporation Novel clostridium difficile dna vaccine
SG11201400916XA (en) 2011-08-22 2014-06-27 Cangene Corp Clostridium difficile antibodies
US10752676B2 (en) * 2011-09-16 2020-08-25 Ucb Biopharma Sprl Neutralising antibodies to the major exotoxins TCDA and TCDB of Clostridium difficile
WO2013071409A1 (en) 2011-11-18 2013-05-23 National Research Council Of Canada (Nrc) Clostridium difficile lipoteichoic acid and uses thereof
KR20140101835A (ko) 2011-12-08 2014-08-20 노파르티스 아게 클로스트리듐 디피실레 톡신-기반 백신
DE102011121238A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-antikörper gegen clostridium difficile toxine
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
SG10201610123UA (en) * 2012-03-02 2017-01-27 Regeneron Pharma Human antibodies to clostridium difficile toxins
GB201206070D0 (en) 2012-04-04 2012-05-16 Health Prot Agency Clostridium difficile antigens
EP2921502A4 (en) * 2012-10-19 2016-09-28 Evec Inc AGAINST TOXIN FROM CLOSTRIDIUM DIFFICILE OR ANTIGENBINDING FRAGMENT SPECIFIC HUMAN ANTIBODY
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
WO2014085749A2 (en) * 2012-11-28 2014-06-05 Cnj Holdings, Inc. Antibodies against clostridium difficile
WO2014144292A2 (en) * 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
AU2014253685B2 (en) * 2013-04-19 2019-07-11 Immuron Limited Methods and compositions for the treatment and/or prophylaxis of clostridium difficile associated disease
US9181632B1 (en) 2013-09-09 2015-11-10 Merck Sharp & Dohme Corp. C.difficile toxin B CROP domain peptides, antibodies and complexes thereof
WO2015100409A2 (en) * 2013-12-26 2015-07-02 Tufts University Methods, compositions and kits for treating a subject using a recombinant neutralizing binding protein
AU2015213593B2 (en) * 2014-02-10 2020-09-03 Igm Biosciences, Inc. IgA multi-specific binding molecules
KR20170041167A (ko) 2014-02-19 2017-04-14 조디 베리 마르부르크 단클론성 항체
EP3662928A1 (en) 2014-04-10 2020-06-10 OBI Pharma Inc. Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof
WO2015184454A1 (en) * 2014-05-30 2015-12-03 Case Western Reserve University Clostridium difficile culture medium
EP2957570B1 (en) 2014-06-20 2019-04-17 Immunimed Inc. Polyclonal antibodies against clostridium difficile and uses thereof
US10513552B2 (en) 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
US10533036B2 (en) * 2015-02-19 2020-01-14 Immune Biosolutions Inc Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof
WO2016156474A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin a
EP3277706A1 (en) 2015-03-31 2018-02-07 VHsquared Limited Polypeptide comprising an immunoglobulin chain variable domain which binds to clostridium difficile toxin b
CN105039262B (zh) * 2015-07-10 2018-07-03 北京科兴中维生物技术有限公司 破伤风类毒素单克隆抗体及其应用
KR20250007054A (ko) 2015-09-04 2025-01-13 프리마토프 테라퓨틱스 인크. 인간화 항-cd40 항체 및 그의 용도
MA44077A (fr) 2015-12-15 2021-05-05 Gilead Sciences Inc Anticorps neutralisants le virus de l'immunodéficience humaine
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2018035407A1 (en) * 2016-08-19 2018-02-22 Enbiotix, Inc. Bacteriophages for neutralizing toxins and methods of use thereof
US10882907B2 (en) 2017-06-21 2021-01-05 Gilead Sciences, Inc. Multispecific antibodies that target HIV GP120 and CD3
JP7347849B2 (ja) * 2018-04-19 2023-09-20 ファースト ライト ダイアグノスティクス， インコーポレイテッド 標的の検出
US20210349082A1 (en) 2018-10-04 2021-11-11 First Light Diagnostics, Inc. Analysis instrument
WO2020231930A1 (en) * 2019-05-11 2020-11-19 The Texas A&M University System Protein inhibitors of clostridium difficile toxin b
WO2021219786A1 (en) * 2020-04-30 2021-11-04 Gottfried Himmler Anti-toxin secretory iga2 preparation
CN111499738B (zh) * 2020-06-03 2022-04-05 郑州师范学院 一种抗艰难梭菌肠毒素a的抗体
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
CN114853896B (zh) * 2020-11-30 2023-05-09 四川大学华西医院 一种抗糖基转移酶a亚单位的纳米抗体及其应用
CN116239683B (zh) * 2023-02-15 2024-12-27 兰州生物制品研究所有限责任公司 一种抗艰难梭菌毒素b的单克隆抗体及其制备方法和应用
CN117720651B (zh) * 2023-12-13 2024-05-31 北京新兴四寰生物技术有限公司 抗艰难梭菌毒素b的单克隆抗体及其应用
WO2025140549A1 (en) * 2023-12-29 2025-07-03 Etinpro (Beijing) Co. Ltd. Immune stimulating anti-hbsag antibody conjugates, pharmaceutical compositions, and therapeutic applications

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012971A2 (de) * 1997-09-10 1999-03-18 Von Eichel Streiber Christoph Aminosäuresequenzen zur therapie und prophylaxe von erkrankungen durch clostridium difficile toxine
WO2001092340A2 (en) * 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
WO2003092630A2 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5244657A (en) 1987-11-24 1993-09-14 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5332583A (en) 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
US5221618A (en) 1987-11-24 1993-06-22 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ　オブ　マサチューセッツ　アット　アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
CA2125396A1 (en) * 1991-12-10 1993-06-24 Wayne A. Marasco Reactive neutralizing human anti-gp 120 recombinant antibody, dna coding the same and use thereof
US5466672A (en) 1992-12-04 1995-11-14 Ophidian Pharmaceuticals, Inc. Therapeutic use of clostridium difficile toxin A
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
AU709586B2 (en) 1994-10-24 1999-09-02 Ophidian Pharmaceuticals, Inc. Vaccine and antitoxin for treatment and prevention of C. difficile disease
GB9621295D0 (en) * 1995-12-07 1996-11-27 Cambridge Antibody Tech Specific binding members,materials and methods
WO1998059053A1 (en) 1997-06-20 1998-12-30 Queen Mary & Westfield College Immonogenic fragments of toxin a of clostridium difficile
EP2305303A3 (en) * 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
IL147765A0 (en) 1999-07-29 2002-08-14 Medarex Inc HUMAN MONOCLONAL ANTIBODIES TO HER2/neu
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
TWI334439B (en) * 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
AU2003224604B2 (en) * 2002-01-28 2007-06-14 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (PSMA)
ATE475431T1 (de) * 2002-03-04 2010-08-15 Imclone Llc Kdr-spezifische humane antikörper und deren anwendung
US7262277B2 (en) * 2002-03-21 2007-08-28 Eli Lilly And Company Antagonistic anti-hFAS ligand human antibodies and fragments thereof
US7396913B2 (en) * 2002-10-14 2008-07-08 Abbott Laboratories Erythropoietin receptor binding antibodies
TWI320716B (en) * 2002-10-14 2010-02-21 Abbott Lab Erythropoietin receptor binding antibodies
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
EP1572736A2 (en) 2002-12-10 2005-09-14 Endocube SAS Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
US20070003561A1 (en) * 2003-07-08 2007-01-04 Sorensen Anders P Binding member towards pneumococcus surface adhesin a protein (psaa)
KR101333449B1 (ko) * 2003-12-10 2013-11-26 메다렉스, 엘.엘.시. Ｉｐ―１０ 항체 및 그의 용도
NZ548821A (en) 2004-02-06 2009-12-24 Univ Massachusetts Antibodies against clostridium difficile toxins and uses thereof
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012971A2 (de) * 1997-09-10 1999-03-18 Von Eichel Streiber Christoph Aminosäuresequenzen zur therapie und prophylaxe von erkrankungen durch clostridium difficile toxine
WO2001092340A2 (en) * 2000-05-26 2001-12-06 Immunex Corporation Use of interleukin-4 antagonists and compositions thereof
WO2003092630A2 (en) * 2002-05-06 2003-11-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CORTHIER, G. et al. 1991 INFECTION AND IMMUNITY, vol. 59, p.1192-1195 *
FREY, S.M. et al. 1992 INFECTION AND IMMUNITY. vol. 60, pages 2488-2492 *
KINK, J.A. et al. 1998 INFECTION AND IMMUNITY, vol. 66, p. 2018-2025 *
SALCEDO, J. et al. 1997 GUT, vol. 41, p. 366-370 *

Also Published As

Publication number Publication date
BE2017C023I2 (enExample) 2024-08-08
HRP20110599T1 (hr) 2011-10-31
JP2011019516A (ja) 2011-02-03
CA2553946C (en) 2019-02-26
LUC00025I1 (enExample) 2017-07-06
US20140120614A1 (en) 2014-05-01
FR17C1025I1 (fr) 2017-08-09
PL1766093T3 (pl) 2011-11-30
JP5319622B2 (ja) 2013-10-16
EP2857418A1 (en) 2015-04-08
US20050287150A1 (en) 2005-12-29
LT2857418T (lt) 2017-09-25
BRPI0507433B8 (pt) 2018-04-10
AU2005320349A1 (en) 2006-08-24
CY1119416T1 (el) 2018-03-07
DK2857418T3 (en) 2017-10-23
EP2270045B1 (en) 2014-12-31
US7625559B2 (en) 2009-12-01
CN101014620A (zh) 2007-08-08
US20120288508A1 (en) 2012-11-15
NO340300B1 (no) 2017-03-27
CY2017022I2 (el) 2017-11-14
PT2270045E (pt) 2015-04-08
AU2005320349B2 (en) 2010-04-08
US9217029B2 (en) 2015-12-22
US8257709B2 (en) 2012-09-04
KR101332994B1 (ko) 2013-11-26
AU2005320349A8 (en) 2008-08-07
ES2533492T3 (es) 2015-04-10
LTPA2017022I1 (lt) 2017-09-11
MXPA06008839A (es) 2008-03-07
EP2857418B1 (en) 2017-07-26
BRPI0507433A (pt) 2007-07-03
JP2013153750A (ja) 2013-08-15
US20100233182A1 (en) 2010-09-16
CA2553946A1 (en) 2005-08-06
NZ580828A (en) 2011-09-30
ATE512986T1 (de) 2011-07-15
WO2006121422A2 (en) 2006-11-16
LUC00025I2 (enExample) 2017-09-08
US20100233181A1 (en) 2010-09-16
NL300881I2 (nl) 2024-07-16
WO2006121422A3 (en) 2007-03-15
NO20063767L (no) 2006-10-02
SI2270045T1 (sl) 2015-06-30
HUE034552T2 (en) 2018-02-28
CN101014620B (zh) 2012-05-09
BRPI0507433B1 (pt) 2018-03-20
EP1766093A2 (en) 2007-03-28
PL2857418T3 (pl) 2017-10-31
KR20070050863A (ko) 2007-05-16
PT2857418T (pt) 2017-10-20
JP5717300B2 (ja) 2015-05-13
KR101332927B1 (ko) 2013-11-26
US8236311B2 (en) 2012-08-07
RS51908B (sr) 2012-02-29
SI1766093T1 (sl) 2011-12-30
EP2270045B8 (en) 2015-02-25
SI2857418T1 (en) 2018-01-31
AU2005320349B8 (en) 2010-04-22
ES2366626T3 (es) 2011-10-24
HK1208873A1 (en) 2016-03-18
JP4588763B2 (ja) 2010-12-01
CY2017022I1 (el) 2017-11-14
ES2643760T3 (es) 2017-11-24
JP2007533330A (ja) 2007-11-22
FR17C1025I2 (fr) 2019-11-15
EP2270045A1 (en) 2011-01-05
HUS1700028I1 (hu) 2017-07-28
PL2270045T3 (pl) 2015-06-30
US20160152694A1 (en) 2016-06-02
NO2017032I1 (no) 2017-07-07
US8609111B2 (en) 2013-12-17
LTC2270045I2 (lt) 2019-12-10
PT1766093E (pt) 2011-08-24
KR20120083534A (ko) 2012-07-25
BRPI0507433C1 (pt) 2021-05-25
HK1102287A1 (en) 2007-11-09
DK2270045T3 (en) 2015-04-07
US20210269511A1 (en) 2021-09-02
NZ548821A (en) 2009-12-24
DK1766093T3 (da) 2011-10-03
US20180208643A1 (en) 2018-07-26
KR20120003017A (ko) 2012-01-09
ZA200606516B (en) 2011-01-26
WO2006121422A8 (en) 2007-04-26
HUE024962T2 (en) 2016-02-29
CY1111860T1 (el) 2015-11-04
EP1766093B1 (en) 2011-06-15
HK1152048A1 (en) 2012-02-17

Similar Documents

Publication Publication Date Title
AU2005320349C1 (en) Antibodies against clostridium difficile toxins and uses thereof
HK1208873B (en) Antibodies against clostridium difficile toxins and uses thereof
HK1152048B (en) Antibodies against clostridium difficile toxins and uses thereof
HK1102287B (en) Antibodies against clostridium difficile toxins and uses thereof

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 20, NO 32, PAGE(S) 3170 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE -NAME INDEX UNDER THE NAME UNIVERSITY OF MASSACHUSETTS AND MEDAREX, INC., APPLICATION NO. 2005320349, UNDER INID(43), CORRECT THE DATE TO READ 16.11.06

Free format text: IN VOL 20, NO 32, PAGE(S) 3140 UNDER THE HEADING APPLICATIONS OPI NAME INDEX UNDER THE NAME UNIVERSITY OF MASSACHUSETTS AND MEDAREX, INC., APPLICATION NO. 2005320349, UNDER INID(43), CORRECT THE DATE TO READ 16.11.06

TH Corrigenda

Free format text: IN VOL 20, NO 32, PAGE(S) 3170 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE -NAME INDEX UNDER THE NAME UNIVERSITY OF MASSACHUSETTS AND MEDAREX, INC., APPLICATION NO. 2005320349, UNDER INID(43), CORRECT THE DATE TO READ 16.11.06

Free format text: IN VOL 20, NO 32, PAGE(S) 3140 UNDER THE HEADING APPLICATIONS OPI NAME INDEX UNDER THE NAME UNIVERSITY OF MASSACHUSETTS AND MEDAREX, INC., APPLICATION NO. 2005320349, UNDER INID(43), CORRECT THE DATE TO READ 16.11.06

TH Corrigenda

Free format text: IN VOL 24, NO 14, PAGE(S) 1619 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAMES UNIVERSITY OF MASSACHUSETTS AND MEDAREX, INC., APPLICATION NO. 2005320349, UNDER INID (72) ADD THE CO-INVENTOR GRAZIANO, ROBERT

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 MAY 2010.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 OCT 2010.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 28 MAY AND 16 JUL 2010

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 OCT

FGA Letters patent sealed or granted (standard patent)
NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: ZINPLAVA BEZLOTOXUMAB (RCH)

Filing date: 20171113

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 OCT 2018

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 15 OCT 2018

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: ZINPLAVA BEZLOTOXUMAB (RCH)

Filing date: 20171113

Extension date: 20300204